<DOC>
	<DOCNO>NCT02211482</DOCNO>
	<brief_summary>The purpose study evaluate antiviral efficacy , safety tolerability dual therapy 3TC DTG initial therapy among naïve HIV patient</brief_summary>
	<brief_title>Dolutegravir-Lamivudine Dual Therapy Naive HIV-Infected Patients : A Pilot Study</brief_title>
	<detailed_description>The purpose study compare antiviral efficacy , safety tolerability dual therapy 3TC DTG initial therapy among naïve HIV patient . Data collect study would inform development large study design evaluate metabolic long term safety , impact inflammatory biomarkers , efficacy , safety cost effectiveness strategy among naïve suppress patient . Primary endpoint : Proportion patient HIV-1 RNA level less 50 copies/mL week 48 . Secondary endpoint : Frequency , type severity adverse event laboratory abnormality , Proportion patient HIV-1 RNA &lt; 1000 copies/mL week 12 , Proportion patient HIV-RNA &lt; 400 week 24 Number type resistance mutation case virologic failure ( define confirm viral 400 copies/mL week 24 copies/mL viral rebound timepoint ) Changes CD4+ lymphocyte count baseline 48 week , Estimation viral decay compare historical data .</detailed_description>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . &gt; 18 year age 2 . Documented HIV1 infection ( positive ELISA plus confirmatory Western Blot ; plasma HIV1 RNA ≥10,000 copies/mL ) 3 . Voluntarily sign date , IRB / IEC approve informed consent form 4 . Agrees take medication study 5 . Screening HIV RNA &gt; 5,000 copies/mL ≤ 100,000 copies/ml 6 . Naïve ARV therapies 7 . CD4 ≥200 cells/mL 8 . Subjects comply protocol requirement 9 . Subject 's general medical condition , investigator 's opinion , interfere assessment completion trial 10 . Patient male female breastfeed pregnant 11 . A female , may eligible : 1. nonchildbearing potential 2. childbearing potential negative pregnancy test Screening Day 1 agrees use one follow method : Complete abstinence penilevaginal intercourse 2 week prior administration IP , throughout study , least 2 week Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) IUD male condom Male partner sterilization confirm male condom Approved hormonal contraception male condom Any method publish data show expected failure rate &lt; 1 % per year use male condom Any contraception method must use least 2 week discontinuation IP 1 . Genotypic resistance lamivudine screening , per IAS USA Panel 2013 2 . Alcohol drug use might impact adherence 3 . Subjects positive Hepatitis B screening ( +HBsAg ) , anticipate need Hepatitis C virus ( HCV ) therapy study 4 . Lactating , pregnancy fertile woman willing pregnant 5 . Concomitant use lower lipid drug , interferon , interleukin2 , cytotoxic chemotherapy , Dofetilide ( pilsicainide ) immunosuppressor study entry 6 . Grade 4 lab abnormality 7 . Primary HIV infection ( indeterminate WB previous negative HIV last 6 month . ) 8 . Opportunistic infection ( CDC C category ) disease and/or clinical condition , investigator 's opinion , would compromise patient 's safety outcome study ; include malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous cell carcinoma , cervical intraepithelial neoplasia 9 . Subjects investigator 's judgment , pose significant suicidality risk 10 . History presence allergy study drug component drug class 11 . Treatment follow agent within 28 day Screening : radiation therapy ; cytotoxic chemotherapeutic agent ; immunomodulators alter immune response treatment HIV1 immunotherapeutic vaccine within 90 day Screening exposure experimental drug experimental vaccine within either 28 day , 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose investigational product 12 . Any acute laboratory abnormality Screening , , opinion Investigator , would preclude subject 's participation study investigational compound 13 . Alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) , ALT ≥ 3xULN bilirubin ≥ 1.5xULN ( &gt; 35 % direct bilirubin ) 14 . Creatinine clearance &lt; 50 mL/min via CockcroftGault method 15 . Subjects moderate severe hepatic impairment ( Class B great ) determine ChildPugh classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV-1 infect patient</keyword>
	<keyword>dual therapy</keyword>
</DOC>